Department of Surgery, James H. Quillen College of Medicine, East Tennessee State University, Campus Box 70575, Johnson City, TN 37614-0575, USA.
Cardiovasc Res. 2013 Mar 1;97(3):432-42. doi: 10.1093/cvr/cvs356. Epub 2012 Dec 3.
We have reported that either toll-like receptor 4 deficiency (TLR4(-/-)) or TLR2 modulation protects against myocardial ischaemia/reperfusion (I/R) injury. The mechanisms involve attenuation of I/R-induced nuclear factor KappaB (NF-κB) activation. MicroRNA-146a (miR-146a) has been reported to target interleukin-1 receptor-associated kinase 1 (IRAK1) and tumor necrosis factor (TNF) receptor associated factor 6 (TRAF6), resulting in inhibiting NF-κB activation. This study examined the role of microRNA-146a in myocardial I/R injury.
We constructed lentivirus expressing miR-146a (LmiR-146a). LmiR-146a was transfected into mouse hearts through the right common carotid artery. The lentivirus vector (LmiR-Con) served as vector control. Untransfected mice served as I/R control. Sham operation served as sham control. Seven days after transfection, the hearts were subjected to ischaemia (60 min) followed by reperfusion (4 h). Myocardial infarct size was analysed by triphenyltetrazolium chloride (TTC) staining. In separate experiments, the hearts were subjected to ischaemia (60 min) followed by reperfusion for up to 7 days. Cardiac function was measured by echocardiography prior to I/R, 3 and 7 days after myocardial I/R. LmiR-146a transfection significantly decreased I/R-induced myocardial infarct size by 55% and prevented I/R-induced decreases in ejection fraction (EF%) and fractional shortening (%FS). LmiR-146a transfection attenuated I/R-induced myocardial apoptosis and caspase-3/7 and -8 activities. LmiR-146a transfection suppresses IRAK1 and TRAF6 expression in the myocardium. In addition, transfection of LmiR-146a prevented I/R-induced NF-κB activation and inflammatory cytokine production.
MicroRNA-146a protects the myocardium from I/R injury. The mechanisms may involve attenuation of NF-κB activation and inflammatory cytokine production by suppressing IRAK1 and TRAF6.
我们曾报道过,Toll 样受体 4 缺失(TLR4(-/-)) 或 TLR2 调节可预防心肌缺血/再灌注(I/R)损伤。其机制涉及抑制 I/R 诱导的核因子 KappaB(NF-κB)激活。miR-146a(miR-146a)已被报道可靶向白细胞介素-1 受体相关激酶 1(IRAK1)和肿瘤坏死因子(TNF)受体相关因子 6(TRAF6),从而抑制 NF-κB 激活。本研究旨在探讨 miR-146a 在心肌 I/R 损伤中的作用。
我们构建了表达 miR-146a 的慢病毒(LmiR-146a)。通过右颈总动脉将 LmiR-146a 转染入小鼠心脏。慢病毒载体(LmiR-Con)作为载体对照。未转染的小鼠作为 I/R 对照。假手术作为假对照。转染 7 天后,心脏缺血(60 分钟),然后再灌注(4 小时)。通过三苯基四氮唑(TTC)染色分析心肌梗死面积。在单独的实验中,心脏缺血(60 分钟),然后再灌注长达 7 天。I/R 前、心肌 I/R 后 3 天和 7 天,通过超声心动图测量心功能。LmiR-146a 转染可使 I/R 诱导的心肌梗死面积减少 55%,并防止 I/R 诱导的射血分数(EF%)和缩短分数(%FS)降低。LmiR-146a 转染可减轻 I/R 诱导的心肌凋亡和 caspase-3/7 和 -8 活性。LmiR-146a 转染可抑制心肌中 IRAK1 和 TRAF6 的表达。此外,LmiR-146a 的转染可防止 I/R 诱导的 NF-κB 激活和炎症细胞因子的产生。
miR-146a 可保护心肌免受 I/R 损伤。其机制可能涉及通过抑制 IRAK1 和 TRAF6 来抑制 NF-κB 激活和炎症细胞因子的产生。